UCB published the latest data in Lancet on the treatment of plaque-like psoriasis

The Lancet journal published two Studies on the treatment of moderate to severe plaque-like psoriasis phase III of the drug bimekizumab.
data from be VIVID and BE READY studies showed that patients treated with bimekizumab had higher levels of skin removal at the 16th week than those treated with placebo or Johnson and Johnson's Stelara (ustekinumab).
two studies were measured by a psoriasis area and severity index (PASI 90) and a researcher's global assessment index (IGA) improvement of at least 90 percent.
UCC has submitted marketing applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
FDA and EMA accepted the company's Application for Biological Agent Licensing (BLA) and Market Licensing (MAA) for bimekizumab, a moderate to severe plaque-like psoriasis, respectively, in September 2020.
psoriasis plaques are caused by abnormally high rate growth of skin cells.
cause of this rapid cell growth is unknown, but problems with the immune system are thought to play a role.
the disease is often prevalent in families, and some genes are associated with psoriasis.
plaque-like psoriasis (the most common type of psoriasis) usually manifests it as one or more small red, silver, shiny patches (plaques) on the scalp, elbows, knees, back, or hips at the beginning of the attack.